INABILITY OF PREEMIES TO PROPERLY ABSORB NUTRIENTS CAN HAVE DEVASTATING CONSEQUENCES
During the final trimester of a woman’s pregnancy, the fetal GI tract goes through tremendous growth and maturation. That all-important development is interrupted in premature infants, meaning that preemies cannot properly absorb nutrients exactly when they need them most.
Babies born with an under-developed GI tract must rely on parenteral nutrition until their gut matures and reaches proper capacity and function. The first weeks until preemies reach “term age” are weeks in which, in the mother’s womb, infants usually grow fastest. This is a crucial period in development: during this time intervention to increase enteral nutrition directly affects the adaptation and development of the GI tract itself, influencing long-term outcomes for these small patients. The major treatment challenge is accelerating growth to help preemies “catch up” with full term infants within a very short timeframe. Every day counts.
A PRESSING MEDICAL NEED IN NEONATOLOGY
Complications of prematurity are the leading cause of death in infants in the first weeks of life (until term equivalent) and the second-leading cause in children under five years of age.
Approximately 140,000 infants are born at or before 32 weeks gestational age in the US and EU. These infants are at high risk of morbidities associated with poor growth, parenteral nutrition and general intolerance to nutrition.
Since roughly 10% of the population is born preterm, it is essential to give our tiny infants the best care by improving long-term growth and neurocognitive outcomes, while reducing complications and morbidities.
NUTRINIA’S NTRA-2112: GIVING PREEMIES A BETTER CHANCE AT NORMAL GROWTH AND DEVELOPMENT
Nutrinia is developing a drug to help premature infants transition faster to enteral nutrition and reach enteral autonomy earlier. It will be used when preterm infants are most vulnerable, which is also the time they can benefit most from treatment: the first weeks following birth. NTRA-2112 is expected to reduce dependency on parenteral nutrition and improve growth and long-term outcomes.